Igor Matushansky, MD, PhD, has joined Immuneering as Chief Medical Officer. In his role, he will direct the company’s clinical activities, providing medical and operational leadership for the development programs.
Company Information
Company
Immuneering
Location
245 MAIN STREET, SECOND FLOOR
Cambridge, Massachusetts, United States
About
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs.
Fundz sees it the moment Immuneering changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealthcareHealth CareMedicalTherapeutics